title: Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.
abstract: We conducted a randomized, double-blind trial to assess the effect of 28.2 μg teriparatide versus placebo (1.4 μg teriparatide) on reduction of the incidence of vertebral fractures. Individuals enrolled in this study included patients with primary osteoporosis with one to five vertebral fractures and capable of self-supported walking. Attention was focused on incident vertebral fractures, change in bone mineral density (BMD) of the lumbar spine, and safety. A total of 316 subjects participated in the study, which lasted up to 131 weeks. Incident vertebral fractures occurred in 3.3% of subjects in the 28.2 μg teriparatide-treated group and 12.6% of subjects in the placebo group during the 78-weeks study period. Kaplan-Meier estimates of risk after 78 weeks were 7.5 and 22.2 % in the teriparatide and placebo groups, respectively, with a relative risk reduction of 66.4% by teriparatide (P = 0.008). Lumbar BMD in the 28.2 μg teriparatide group increased significantly by 4.4 ± 4.7 % at 78 weeks, which was significantly higher than the corresponding data in the placebo group (P = 0.001). Adverse events were observed in 86.7% of individuals in the teriparatide group and 86.1% of those in the placebo group. In conclusion, weekly injection of a low-dose of teriparatide (28.2 μg) reduced the risk of incident vertebral fractures and increased lumbar BMD.
authors: Katsuragi Hospital, 2-33-1 Habu-cho, Kishiwada, Osaka, 596-0825, Japan, fujita@katsuragi-hosp.or.jp.
authors: Takuo
authors: T
authors: Fujita
authors: Masao
authors: M
authors: Fukunaga
authors: Akira
authors: A
authors: Itabashi
authors: Kiichiro
authors: K
authors: Tsutani
authors: Toshitaka
authors: T
authors: Nakamura
mesh_terms: D000368:Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007267:Injections; D008159:Lumbar Vertebrae; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control*; D012307:Risk Factors; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control*; D019379:Teriparatide / Q000008:administration & dosage*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide
references: Endocrinology. 1989 Mar;124(3):1247-53
references: 2645113
references: J Bone Miner Res. 2001 Oct;16(10):1846-53
references: 11585349
references: Calcif Tissue Int. 1987 Nov;41(5):290-2
references: 2825936
references: Endocrinol Jpn. 1972 Dec;19(6):571-7
references: 4679234
references: J Bone Miner Res. 2003 Mar;18(3):539-43
references: 12619939
references: Biochem Biophys Res Commun. 1991 Aug 15;178(3):953-8
references: 1872875
references: Bone. 2000 Aug;27(2):311-8
references: 10913928
references: J Clin Invest. 1989 Jan;83(1):60-5
references: 2910920
references: J Clin Endocrinol Metab. 1991 Dec;73(6):1345-51
references: 1955517
references: Cell Metab. 2010 Feb 3;11(2):161-71
references: 20142103
references: Endocr J. 2008 Jul;55(3):613-6
references: 18520104
references: Endocrinology. 2001 Oct;142(10):4349-56
references: 11564695
references: Bone. 2010 Sep;47(3):493-502
references: 20580870
references: J Clin Endocrinol Metab. 2012 Sep;97(9):3097-106
references: 22723322
references: J Musculoskelet Neuronal Interact. 2006 Oct-Dec;6(4):358-9
references: 17185824
references: J Bone Miner Res. 1993 Sep;8(9):1137-48
references: 8237484
references: J Bone Miner Res. 2010 Feb;25(2):190-9
references: 19594295
references: Genes Dev. 2008 Nov 1;22(21):2968-79
references: 18981475
references: J Bone Miner Res. 1995 Apr;10(4):518-23
references: 7610921
references: J Bone Miner Res. 2003 Nov;18(11):1932-41
references: 14606504
references: Osteoporos Int. 1999;9(4):296-306
references: 10550446
references: Osteoporos Int. 2013 Jan;24(1):219-26
references: 23093347